Review



pdgfr beta protein  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc pdgfr beta protein
    Stromal <t>PDGFR-beta</t> expression analysis on tissue samples of serous ovarian cancer patients. A – B PDGFR-beta immunostaining in serous ovarian carcinoma: A Absent PDGFR-beta staining in the tumor cells, while the surrounding stroma shows strong expression. B Strong PDGFR-beta staining in the tumor and the stroma. C Stromal PDGFR-beta expression correlates significantly with histopathological grading ( p = 0.003). D In high-grade serous ovarian cancer strong PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.038). E After dividing the cohort with respect to therapy regimens, a significant association is only seen in patients treated with bevacizumab therapy ( p = 0.037). F In patients that did not receive bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.343). G Moreover, in the cohort of ovarian cancer patients with no residual disease after cytoreductive surgery, treated with bevacizumab, high PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.028). H In patients with residual disease after cytoreductive surgery, that received bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.392).For all Kaplan–Meier analyzes he cohort was divided into two groups according to the intensity of stromal PDGFR-beta staining (weak to moderate staining vs. strong staining)
    Pdgfr Beta Protein, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 92/100, based on 16 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgfr+beta+protein/PDGF+Receptor+beta+Rabbit+mAb/pmc11759463-91-4-8
    Average 92 stars, based on 16 article reviews
    pdgfr beta protein - by Bioz Stars, 2026-09
    92/100 stars

    Images

    1) Product Images from "Stromal PDGFR-beta expression is a prognostic factor in high-grade serous ovarian cancer patients but is it also predictive for response to antiangiogenic treatment?"

    Article Title: Stromal PDGFR-beta expression is a prognostic factor in high-grade serous ovarian cancer patients but is it also predictive for response to antiangiogenic treatment?

    Journal: Journal of Cancer Research and Clinical Oncology

    doi: 10.1007/s00432-025-06090-4

    Stromal PDGFR-beta expression analysis on tissue samples of serous ovarian cancer patients. A – B PDGFR-beta immunostaining in serous ovarian carcinoma: A Absent PDGFR-beta staining in the tumor cells, while the surrounding stroma shows strong expression. B Strong PDGFR-beta staining in the tumor and the stroma. C Stromal PDGFR-beta expression correlates significantly with histopathological grading ( p = 0.003). D In high-grade serous ovarian cancer strong PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.038). E After dividing the cohort with respect to therapy regimens, a significant association is only seen in patients treated with bevacizumab therapy ( p = 0.037). F In patients that did not receive bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.343). G Moreover, in the cohort of ovarian cancer patients with no residual disease after cytoreductive surgery, treated with bevacizumab, high PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.028). H In patients with residual disease after cytoreductive surgery, that received bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.392).For all Kaplan–Meier analyzes he cohort was divided into two groups according to the intensity of stromal PDGFR-beta staining (weak to moderate staining vs. strong staining)
    Figure Legend Snippet: Stromal PDGFR-beta expression analysis on tissue samples of serous ovarian cancer patients. A – B PDGFR-beta immunostaining in serous ovarian carcinoma: A Absent PDGFR-beta staining in the tumor cells, while the surrounding stroma shows strong expression. B Strong PDGFR-beta staining in the tumor and the stroma. C Stromal PDGFR-beta expression correlates significantly with histopathological grading ( p = 0.003). D In high-grade serous ovarian cancer strong PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.038). E After dividing the cohort with respect to therapy regimens, a significant association is only seen in patients treated with bevacizumab therapy ( p = 0.037). F In patients that did not receive bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.343). G Moreover, in the cohort of ovarian cancer patients with no residual disease after cytoreductive surgery, treated with bevacizumab, high PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.028). H In patients with residual disease after cytoreductive surgery, that received bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.392).For all Kaplan–Meier analyzes he cohort was divided into two groups according to the intensity of stromal PDGFR-beta staining (weak to moderate staining vs. strong staining)

    Techniques Used: Expressing, Immunostaining, Staining

    Correlation between histopathological parameters and stromal PDGFR-beta and tumoral VEGFR-2 expression in serous/ serous-papillary ovarian cancer
    Figure Legend Snippet: Correlation between histopathological parameters and stromal PDGFR-beta and tumoral VEGFR-2 expression in serous/ serous-papillary ovarian cancer

    Techniques Used: Expressing

    Related Articles

    Expressing:

    Article Title: Stromal PDGFR-beta expression is a prognostic factor in high-grade serous ovarian cancer patients but is it also predictive for response to antiangiogenic treatment?
    Article Snippet: Slides were deparaffinized and exposed to heat-induced antigen retrieval for 5 min in an autoclave at 121 °C in pH 9.0 Target Retrieveal Solution (Agilent, Santa Clara, CA, USA).Slides were deparaffinized and exposed to heat-induced antigen retrieval for 5 min in an autoclave at 121 °C in pH 9.0 Target Retrieveal Solution (Agilent, Santa Clara, CA, USA).. Primary antibody specific against PDGFR-beta protein (rabbit monoclonal, Cell Signaling Technology, Danvers, MA, USA, clone C82A3) was applied at 37 °C for 60 min at a dilution of 1:150.. Primary antibody specific against VEGFR-2 protein (rabbit monoclonal, Cell Signaling Technology, Danvers, MA, USA clone 55B11) was applied at 37 °C for 60 min at a dilution of 1:150.Primary antibody specific against VEGFR-2 protein (rabbit monoclonal, Cell Signaling Technology, Danvers, MA, USA clone 55B11) was applied at 37 °C for 60 min at a dilution of 1:150.

    Article Title: Stromal PDGFR-beta expression is a prognostic factor in high-grade serous ovarian cancer patients but is it also predictive for response to antiangiogenic treatment?
    Article Snippet: Slides were deparaffinized and exposed to heat-induced antigen retrieval for 5 min in an autoclave at 121 °C in pH 9.0 Target Retrieveal Solution (Agilent, Santa Clara, CA, USA).Slides were deparaffinized and exposed to heat-induced antigen retrieval for 5 min in an autoclave at 121 °C in pH 9.0 Target Retrieveal Solution (Agilent, Santa Clara, CA, USA).. Primary antibody specific against PDGFR-beta protein (rabbit monoclonal, Cell Signaling Technology, Danvers, MA, USA, clone C82A3) was applied at 37 °C for 60 min at a dilution of 1:150.. Primary antibody specific against VEGFR-2 protein (rabbit monoclonal, Cell Signaling Technology, Danvers, MA, USA clone 55B11) was applied at 37 °C for 60 min at a dilution of 1:150.Primary antibody specific against VEGFR-2 protein (rabbit monoclonal, Cell Signaling Technology, Danvers, MA, USA clone 55B11) was applied at 37 °C for 60 min at a dilution of 1:150.

    Immunostaining:

    Article Title: Stromal PDGFR-beta expression is a prognostic factor in high-grade serous ovarian cancer patients but is it also predictive for response to antiangiogenic treatment?
    Article Snippet: Slides were deparaffinized and exposed to heat-induced antigen retrieval for 5 min in an autoclave at 121 °C in pH 9.0 Target Retrieveal Solution (Agilent, Santa Clara, CA, USA).Slides were deparaffinized and exposed to heat-induced antigen retrieval for 5 min in an autoclave at 121 °C in pH 9.0 Target Retrieveal Solution (Agilent, Santa Clara, CA, USA).. Primary antibody specific against PDGFR-beta protein (rabbit monoclonal, Cell Signaling Technology, Danvers, MA, USA, clone C82A3) was applied at 37 °C for 60 min at a dilution of 1:150.. Primary antibody specific against VEGFR-2 protein (rabbit monoclonal, Cell Signaling Technology, Danvers, MA, USA clone 55B11) was applied at 37 °C for 60 min at a dilution of 1:150.Primary antibody specific against VEGFR-2 protein (rabbit monoclonal, Cell Signaling Technology, Danvers, MA, USA clone 55B11) was applied at 37 °C for 60 min at a dilution of 1:150.

    Article Title: Stromal PDGFR-beta expression is a prognostic factor in high-grade serous ovarian cancer patients but is it also predictive for response to antiangiogenic treatment?
    Article Snippet: Slides were deparaffinized and exposed to heat-induced antigen retrieval for 5 min in an autoclave at 121 °C in pH 9.0 Target Retrieveal Solution (Agilent, Santa Clara, CA, USA).Slides were deparaffinized and exposed to heat-induced antigen retrieval for 5 min in an autoclave at 121 °C in pH 9.0 Target Retrieveal Solution (Agilent, Santa Clara, CA, USA).. Primary antibody specific against PDGFR-beta protein (rabbit monoclonal, Cell Signaling Technology, Danvers, MA, USA, clone C82A3) was applied at 37 °C for 60 min at a dilution of 1:150.. Primary antibody specific against VEGFR-2 protein (rabbit monoclonal, Cell Signaling Technology, Danvers, MA, USA clone 55B11) was applied at 37 °C for 60 min at a dilution of 1:150.Primary antibody specific against VEGFR-2 protein (rabbit monoclonal, Cell Signaling Technology, Danvers, MA, USA clone 55B11) was applied at 37 °C for 60 min at a dilution of 1:150.

    Staining:

    Article Title: Stromal PDGFR-beta expression is a prognostic factor in high-grade serous ovarian cancer patients but is it also predictive for response to antiangiogenic treatment?
    Article Snippet: Slides were deparaffinized and exposed to heat-induced antigen retrieval for 5 min in an autoclave at 121 °C in pH 9.0 Target Retrieveal Solution (Agilent, Santa Clara, CA, USA).Slides were deparaffinized and exposed to heat-induced antigen retrieval for 5 min in an autoclave at 121 °C in pH 9.0 Target Retrieveal Solution (Agilent, Santa Clara, CA, USA).. Primary antibody specific against PDGFR-beta protein (rabbit monoclonal, Cell Signaling Technology, Danvers, MA, USA, clone C82A3) was applied at 37 °C for 60 min at a dilution of 1:150.. Primary antibody specific against VEGFR-2 protein (rabbit monoclonal, Cell Signaling Technology, Danvers, MA, USA clone 55B11) was applied at 37 °C for 60 min at a dilution of 1:150.Primary antibody specific against VEGFR-2 protein (rabbit monoclonal, Cell Signaling Technology, Danvers, MA, USA clone 55B11) was applied at 37 °C for 60 min at a dilution of 1:150.

    Article Title: Stromal PDGFR-beta expression is a prognostic factor in high-grade serous ovarian cancer patients but is it also predictive for response to antiangiogenic treatment?
    Article Snippet: Slides were deparaffinized and exposed to heat-induced antigen retrieval for 5 min in an autoclave at 121 °C in pH 9.0 Target Retrieveal Solution (Agilent, Santa Clara, CA, USA).Slides were deparaffinized and exposed to heat-induced antigen retrieval for 5 min in an autoclave at 121 °C in pH 9.0 Target Retrieveal Solution (Agilent, Santa Clara, CA, USA).. Primary antibody specific against PDGFR-beta protein (rabbit monoclonal, Cell Signaling Technology, Danvers, MA, USA, clone C82A3) was applied at 37 °C for 60 min at a dilution of 1:150.. Primary antibody specific against VEGFR-2 protein (rabbit monoclonal, Cell Signaling Technology, Danvers, MA, USA clone 55B11) was applied at 37 °C for 60 min at a dilution of 1:150.Primary antibody specific against VEGFR-2 protein (rabbit monoclonal, Cell Signaling Technology, Danvers, MA, USA clone 55B11) was applied at 37 °C for 60 min at a dilution of 1:150.



    Similar Products

    recombinant mouse pdgfr β fc chimera  (R&D Systems)
    93
    R&D Systems recombinant mouse pdgfr β fc chimera
    Recombinant Mouse Pdgfr β Fc Chimera, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgfr+beta+protein/Recombinant+Mouse+PDGF+R+beta+Fc+Chimera+Protein%2C+CF/bio_rxiv__2025__07__09__664016-44-0-5
    Average 93 stars, based on 1 article reviews
    recombinant mouse pdgfr β fc chimera - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    pdgfr beta protein  (Cell Signaling Technology Inc)
    92
    Cell Signaling Technology Inc pdgfr beta protein
    Stromal <t>PDGFR-beta</t> expression analysis on tissue samples of serous ovarian cancer patients. A – B PDGFR-beta immunostaining in serous ovarian carcinoma: A Absent PDGFR-beta staining in the tumor cells, while the surrounding stroma shows strong expression. B Strong PDGFR-beta staining in the tumor and the stroma. C Stromal PDGFR-beta expression correlates significantly with histopathological grading ( p = 0.003). D In high-grade serous ovarian cancer strong PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.038). E After dividing the cohort with respect to therapy regimens, a significant association is only seen in patients treated with bevacizumab therapy ( p = 0.037). F In patients that did not receive bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.343). G Moreover, in the cohort of ovarian cancer patients with no residual disease after cytoreductive surgery, treated with bevacizumab, high PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.028). H In patients with residual disease after cytoreductive surgery, that received bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.392).For all Kaplan–Meier analyzes he cohort was divided into two groups according to the intensity of stromal PDGFR-beta staining (weak to moderate staining vs. strong staining)
    Pdgfr Beta Protein, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgfr+beta+protein/PDGF+Receptor+beta+Rabbit+mAb/pmc11759463-91-4-8
    Average 92 stars, based on 1 article reviews
    pdgfr beta protein - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier
    pdgfr β fc chimera protein  (R&D Systems)
    92
    R&D Systems pdgfr β fc chimera protein
    Stromal <t>PDGFR-beta</t> expression analysis on tissue samples of serous ovarian cancer patients. A – B PDGFR-beta immunostaining in serous ovarian carcinoma: A Absent PDGFR-beta staining in the tumor cells, while the surrounding stroma shows strong expression. B Strong PDGFR-beta staining in the tumor and the stroma. C Stromal PDGFR-beta expression correlates significantly with histopathological grading ( p = 0.003). D In high-grade serous ovarian cancer strong PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.038). E After dividing the cohort with respect to therapy regimens, a significant association is only seen in patients treated with bevacizumab therapy ( p = 0.037). F In patients that did not receive bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.343). G Moreover, in the cohort of ovarian cancer patients with no residual disease after cytoreductive surgery, treated with bevacizumab, high PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.028). H In patients with residual disease after cytoreductive surgery, that received bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.392).For all Kaplan–Meier analyzes he cohort was divided into two groups according to the intensity of stromal PDGFR-beta staining (weak to moderate staining vs. strong staining)
    Pdgfr β Fc Chimera Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgfr+beta+protein/Recombinant+Human+PDGF+R+beta+Fc+Chimera+Protein/bio_rxiv__2024__05__14__594040-57-4-7
    Average 92 stars, based on 1 article reviews
    pdgfr β fc chimera protein - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier
    protein z for identifying a platelet-derived growth factor receptor pdgfr beta pdgfrβ  (Affibody)
    90
    Affibody protein z for identifying a platelet-derived growth factor receptor pdgfr beta pdgfrβ
    Stromal <t>PDGFR-beta</t> expression analysis on tissue samples of serous ovarian cancer patients. A – B PDGFR-beta immunostaining in serous ovarian carcinoma: A Absent PDGFR-beta staining in the tumor cells, while the surrounding stroma shows strong expression. B Strong PDGFR-beta staining in the tumor and the stroma. C Stromal PDGFR-beta expression correlates significantly with histopathological grading ( p = 0.003). D In high-grade serous ovarian cancer strong PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.038). E After dividing the cohort with respect to therapy regimens, a significant association is only seen in patients treated with bevacizumab therapy ( p = 0.037). F In patients that did not receive bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.343). G Moreover, in the cohort of ovarian cancer patients with no residual disease after cytoreductive surgery, treated with bevacizumab, high PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.028). H In patients with residual disease after cytoreductive surgery, that received bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.392).For all Kaplan–Meier analyzes he cohort was divided into two groups according to the intensity of stromal PDGFR-beta staining (weak to moderate staining vs. strong staining)
    Protein Z For Identifying A Platelet Derived Growth Factor Receptor Pdgfr Beta Pdgfrβ, supplied by Affibody, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgfr+beta+protein/protein+z+for+identifying+a+platelet+derived+growth+factor+receptor+pdgfr+beta+pdgfr%CE%B2/pmc11797645-44-0-15
    Average 90 stars, based on 1 article reviews
    protein z for identifying a platelet-derived growth factor receptor pdgfr beta pdgfrβ - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    recombinant human pdgfr higg1 fc chimeric fusion protein  (R&D Systems Hematology)
    92
    R&D Systems Hematology recombinant human pdgfr higg1 fc chimeric fusion protein
    Stromal <t>PDGFR-beta</t> expression analysis on tissue samples of serous ovarian cancer patients. A – B PDGFR-beta immunostaining in serous ovarian carcinoma: A Absent PDGFR-beta staining in the tumor cells, while the surrounding stroma shows strong expression. B Strong PDGFR-beta staining in the tumor and the stroma. C Stromal PDGFR-beta expression correlates significantly with histopathological grading ( p = 0.003). D In high-grade serous ovarian cancer strong PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.038). E After dividing the cohort with respect to therapy regimens, a significant association is only seen in patients treated with bevacizumab therapy ( p = 0.037). F In patients that did not receive bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.343). G Moreover, in the cohort of ovarian cancer patients with no residual disease after cytoreductive surgery, treated with bevacizumab, high PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.028). H In patients with residual disease after cytoreductive surgery, that received bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.392).For all Kaplan–Meier analyzes he cohort was divided into two groups according to the intensity of stromal PDGFR-beta staining (weak to moderate staining vs. strong staining)
    Recombinant Human Pdgfr Higg1 Fc Chimeric Fusion Protein, supplied by R&D Systems Hematology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgfr+beta+protein/Recombinant+Human+PDGF+R+beta+Fc+Chimera+Protein/us11136398-886-1-7
    Average 92 stars, based on 1 article reviews
    recombinant human pdgfr higg1 fc chimeric fusion protein - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier
    recombinant human pdgfr β protein  (Sino Biological)
    90
    Sino Biological recombinant human pdgfr β protein
    Stromal <t>PDGFR-beta</t> expression analysis on tissue samples of serous ovarian cancer patients. A – B PDGFR-beta immunostaining in serous ovarian carcinoma: A Absent PDGFR-beta staining in the tumor cells, while the surrounding stroma shows strong expression. B Strong PDGFR-beta staining in the tumor and the stroma. C Stromal PDGFR-beta expression correlates significantly with histopathological grading ( p = 0.003). D In high-grade serous ovarian cancer strong PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.038). E After dividing the cohort with respect to therapy regimens, a significant association is only seen in patients treated with bevacizumab therapy ( p = 0.037). F In patients that did not receive bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.343). G Moreover, in the cohort of ovarian cancer patients with no residual disease after cytoreductive surgery, treated with bevacizumab, high PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.028). H In patients with residual disease after cytoreductive surgery, that received bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.392).For all Kaplan–Meier analyzes he cohort was divided into two groups according to the intensity of stromal PDGFR-beta staining (weak to moderate staining vs. strong staining)
    Recombinant Human Pdgfr β Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgfr+beta+protein/Human+CD140b+%2F+PDGFRB+Protein/pmc07296008-43-0-9
    Average 90 stars, based on 1 article reviews
    recombinant human pdgfr β protein - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    recombinant human cf pdgfr β fc  (R&D Systems)
    92
    R&D Systems recombinant human cf pdgfr β fc
    Stromal <t>PDGFR-beta</t> expression analysis on tissue samples of serous ovarian cancer patients. A – B PDGFR-beta immunostaining in serous ovarian carcinoma: A Absent PDGFR-beta staining in the tumor cells, while the surrounding stroma shows strong expression. B Strong PDGFR-beta staining in the tumor and the stroma. C Stromal PDGFR-beta expression correlates significantly with histopathological grading ( p = 0.003). D In high-grade serous ovarian cancer strong PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.038). E After dividing the cohort with respect to therapy regimens, a significant association is only seen in patients treated with bevacizumab therapy ( p = 0.037). F In patients that did not receive bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.343). G Moreover, in the cohort of ovarian cancer patients with no residual disease after cytoreductive surgery, treated with bevacizumab, high PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.028). H In patients with residual disease after cytoreductive surgery, that received bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.392).For all Kaplan–Meier analyzes he cohort was divided into two groups according to the intensity of stromal PDGFR-beta staining (weak to moderate staining vs. strong staining)
    Recombinant Human Cf Pdgfr β Fc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgfr+beta+protein/Recombinant+Human+PDGF+R+beta+Fc+Chimera+Protein%2C+CF/pmc06553959-148-0-5
    Average 92 stars, based on 1 article reviews
    recombinant human cf pdgfr β fc - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier
    pdgfr-β protein  (Eurofins)
    90
    Eurofins pdgfr-β protein
    Stromal <t>PDGFR-beta</t> expression analysis on tissue samples of serous ovarian cancer patients. A – B PDGFR-beta immunostaining in serous ovarian carcinoma: A Absent PDGFR-beta staining in the tumor cells, while the surrounding stroma shows strong expression. B Strong PDGFR-beta staining in the tumor and the stroma. C Stromal PDGFR-beta expression correlates significantly with histopathological grading ( p = 0.003). D In high-grade serous ovarian cancer strong PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.038). E After dividing the cohort with respect to therapy regimens, a significant association is only seen in patients treated with bevacizumab therapy ( p = 0.037). F In patients that did not receive bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.343). G Moreover, in the cohort of ovarian cancer patients with no residual disease after cytoreductive surgery, treated with bevacizumab, high PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.028). H In patients with residual disease after cytoreductive surgery, that received bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.392).For all Kaplan–Meier analyzes he cohort was divided into two groups according to the intensity of stromal PDGFR-beta staining (weak to moderate staining vs. strong staining)
    Pdgfr β Protein, supplied by Eurofins, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgfr+beta+protein/rno+pdgf+c+f+gcg+gaa+gcg+cat+cta+tat+ct/pm30241010-380-10-17
    Average 90 stars, based on 1 article reviews
    pdgfr-β protein - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Stromal PDGFR-beta expression analysis on tissue samples of serous ovarian cancer patients. A – B PDGFR-beta immunostaining in serous ovarian carcinoma: A Absent PDGFR-beta staining in the tumor cells, while the surrounding stroma shows strong expression. B Strong PDGFR-beta staining in the tumor and the stroma. C Stromal PDGFR-beta expression correlates significantly with histopathological grading ( p = 0.003). D In high-grade serous ovarian cancer strong PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.038). E After dividing the cohort with respect to therapy regimens, a significant association is only seen in patients treated with bevacizumab therapy ( p = 0.037). F In patients that did not receive bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.343). G Moreover, in the cohort of ovarian cancer patients with no residual disease after cytoreductive surgery, treated with bevacizumab, high PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.028). H In patients with residual disease after cytoreductive surgery, that received bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.392).For all Kaplan–Meier analyzes he cohort was divided into two groups according to the intensity of stromal PDGFR-beta staining (weak to moderate staining vs. strong staining)

    Journal: Journal of Cancer Research and Clinical Oncology

    Article Title: Stromal PDGFR-beta expression is a prognostic factor in high-grade serous ovarian cancer patients but is it also predictive for response to antiangiogenic treatment?

    doi: 10.1007/s00432-025-06090-4

    Figure Lengend Snippet: Stromal PDGFR-beta expression analysis on tissue samples of serous ovarian cancer patients. A – B PDGFR-beta immunostaining in serous ovarian carcinoma: A Absent PDGFR-beta staining in the tumor cells, while the surrounding stroma shows strong expression. B Strong PDGFR-beta staining in the tumor and the stroma. C Stromal PDGFR-beta expression correlates significantly with histopathological grading ( p = 0.003). D In high-grade serous ovarian cancer strong PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.038). E After dividing the cohort with respect to therapy regimens, a significant association is only seen in patients treated with bevacizumab therapy ( p = 0.037). F In patients that did not receive bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.343). G Moreover, in the cohort of ovarian cancer patients with no residual disease after cytoreductive surgery, treated with bevacizumab, high PDGFR-beta expression correlates significantly with shorter overall survival ( p = 0.028). H In patients with residual disease after cytoreductive surgery, that received bevacizumab therapy, PDGFR-beta expression levels have no significant impact on overall survival ( p = 0.392).For all Kaplan–Meier analyzes he cohort was divided into two groups according to the intensity of stromal PDGFR-beta staining (weak to moderate staining vs. strong staining)

    Article Snippet: Primary antibody specific against PDGFR-beta protein (rabbit monoclonal, Cell Signaling Technology, Danvers, MA, USA, clone C82A3) was applied at 37 °C for 60 min at a dilution of 1:150.

    Techniques: Expressing, Immunostaining, Staining

    Correlation between histopathological parameters and stromal PDGFR-beta and tumoral VEGFR-2 expression in serous/ serous-papillary ovarian cancer

    Journal: Journal of Cancer Research and Clinical Oncology

    Article Title: Stromal PDGFR-beta expression is a prognostic factor in high-grade serous ovarian cancer patients but is it also predictive for response to antiangiogenic treatment?

    doi: 10.1007/s00432-025-06090-4

    Figure Lengend Snippet: Correlation between histopathological parameters and stromal PDGFR-beta and tumoral VEGFR-2 expression in serous/ serous-papillary ovarian cancer

    Article Snippet: Primary antibody specific against PDGFR-beta protein (rabbit monoclonal, Cell Signaling Technology, Danvers, MA, USA, clone C82A3) was applied at 37 °C for 60 min at a dilution of 1:150.

    Techniques: Expressing